top of page

Search Results

Search this site

257 results found

Research Articles (191)

  • In Vitro Cosmetic Testing Is Quietly Dying

    A positive result in a cell culture dish once supported many cosmetic claims: a collagen marker increased, or an inflammatory pathway decreased. But consumers buy products for what happens on their skin. As claims become more ambitious, evidence standards are shifting. In vitro remains valuable, but relying on it as the entire proof story is increasingly outdated. Why are in vitro skin models losing credibility? Regulators and consumers are asking a harder question: “Does this model predict what happens in real human skin?” In vitro systems offer valuable biological insight, but they simplify a complex organ. Skin is an ecosystem of immune signalling, vascular influence, environmental exposure and microbes. What can in vitro never fully capture? Skin responses vary between individuals due to age, genetics, hormones, lifestyle and microbiome differences. The microbiome is especially complex, involving microbial interactions, immunity, metabolites and barrier function. Simplified models can provide valuable insights, but they cannot fully predict real-world skin responses. Where does in vitro still earn its place and where does it become a trap? In vitro remains a powerful tool in cosmetic science when used for the right questions. It is valuable for: · Screening ingredients · Supporting safety assessment · Comparing formulations The risk is turning a biological signal into a consumer promise. A fibroblast producing more collagen does not prove fewer wrinkles, and a growth assay does not prove improved microbiome health. The mistake is not using in vitro; it is asking it to prove more than it can. What does in vivo multi-omics actually look like? Multi-omics sounds complex, but the principle is simple: measure multiple biological layers together. A study may combine microbiome sequencing, metabolomics, transcriptomics and clinical measurements such as hydration, redness or barrier function. Instead of asking “did one marker change?”, we can ask: • Did the product alter microbial communities? • Did those changes influence biological pathways? • Did skin function improve? • Did consumers experience a measurable benefit? This moves cosmetic testing from isolated signals towards a systems-level understanding of skin. Will regulators ban in vitro-only substantiation? Probably not. The bigger shift is the rising expectation for evidence quality. Regulators are increasingly focused on whether evidence matches the claim. Validated in vitro methods remain appropriate for safety and mechanistic questions, but claims involving complex outcomes such as inflammation or visible ageing require evidence that reflects real-world effects. How fast should brands move? Strategically, not universally. Routine safety testing and early screening still have a place, but flagship products built on complex biological claims must move to a relevant human evidence base. In vitro is for understanding. Human studies for proving. Multi-omics for explaining. The strongest brands will not abandon laboratory models. They will use them within a fuller evidence ecosystem.

  • Vaginal Multiomics: Understanding the System, Not the Signal

    The vaginal ecosystem is not just a microbial community. It is a host-microbe system shaped by hormones, immunity, metabolites, and local chemistry. Multiomics, a combination of microbiome, metabolome, immune signals, and genomics, moves the field beyond "which bacteria are present?" to what they are doing, how the host responds, and what that means for health. What we know This approach has transformed understanding of the vaginal ecosystem, revealing complex host–microbe interactions, functional diversity, and links to BV, reproductive outcomes, and gynaecological cancers 1. The mix of small molecules in the vagina (metabolites) is one of the best ways to understand its state. Certain fats (lipids) help show levels of inflammation, while amino-acid by-products reflect which bacteria are present and the pH 2. The vaginal environment is different for everyone and changes over time. Simple “normal” vs “abnormal” labels miss important differences between people 3. Recent advances include AI-powered diagnostic models that integrate microbiome and metabolome data for improved BV detection 4. Impact and potential Vaginal multiomics opens real innovation pathways. Microbiome-compatible formulation: Designing intimate care that avoids disrupting the vaginal microbiome Prebiotic and postbiotic development: Targeting favourable metabolic environments, not simply eliminating bacteria. Longitudinal testing and claims: Shift from single timepoint testing to tracking changes over time (e.g. across cycles, treatment use), enabling more meaningful and defensible claims. Subtype-driven product design: Move beyond one-size-fits-all “intimate care” by developing products tailored to different dysbiosis or symptom subtypes identified through multiomics. Our position At Sequential, we approach the skin as an ecosystem, not a single pathway. Our focus is on generating measurable, real-world evidence of how formulations interact with both the barrier and the microbiome simultaneously. Using integrated multi-omics approaches, we can quantify changes in lipid composition, protein expression, microbial activity, and overall skin resilience over time. By testing formulations on diverse skin types and environments, using our global sample database, we generate insights that reflect real-world use rather than idealised conditions. References 1. Ottinger, S., et al. (2024). The human vaginal microbiota. Curr Opin Microbiol, 77, 102422. 2. Bokulich, N., et al. (2022). Multi-omics integration in the cervicovaginal microenvironment. PLoS Comput Biol, 18, e1009876. 3. Challa, A., et al. (2024). Multi-omics biomarkers of bacterial vaginosis. J Eur Acad Dermatol Venereol, 38, 1152–1165. 4. Saluzzo, S., et al. (2024). AI-powered multiomics in bacterial vaginosis. J Eur Acad Dermatol Venereol, 38,999 -1000.

  • Your Skin Barrier Isn't Working Alone

    The skin barrier is often described as a wall. In reality, it’s more like a living ecosystem. At its surface sits the skin microbiome, a complex community of bacteria, fungi, and viruses that don’t just exist on the skin, but actively help it function. Rather than being passive, the microbiome works alongside the physical, chemical, and immune layers of the barrier to maintain resilience, regulate inflammation, and protect against environmental stress. When this relationship is balanced, skin performs optimally. When it’s disrupted, both barrier function and skin health can decline. What we know The microbiome acts as a co-regulator of skin function, working alongside the barrier and immune system 1. The microbiome is a diverse, site-specific ecosystem. Oily, moist, and dry areas host distinct communities 2,3. Commensal microbes actively support barrier integrity through effects on keratinocytes and lipid balance 1, 4. Dysbiosis, through reduced diversity, is associated with conditions such as acne, atopic dermatitis, and psoriasis, often alongside barrier disruption 1, 5. Industry impact and potential For formulation, this changes the goalposts. It’s no longer enough to protect the barrier or consider the microbiome in isolation. The focus should be on supporting the system as a whole. Barrier-first design: Prioritising formulations that maintain hydration, pH, and lipid balance to create conditions in which beneficial microbes thrive. Microbiome-compatible actives: Using prebiotics, postbiotics, and fermented ingredients where evidence supports functional benefit. Precision skincare: Leveraging microbiome profiling and multi-omic data to match products to different skin states, environments, and life stages. Our position At Sequential, we approach the skin as an ecosystem, not a single pathway. Our focus is on generating measurable, real-world evidence of how formulations interact with both the barrier and the microbiome simultaneously. Using integrated multi-omics approaches, we can quantify changes in lipid composition, protein expression, microbial activity, and overall skin resilience over time. By testing formulations on diverse skin types and environments, using our global sample database, we generate insights that reflect real-world use rather than idealised conditions. References Lee, H, et al. (2022). Skin Barrier Function and the Microbiome. Int J Mol Sci, 23. Smythe, P, et al. (2023). The Skin Microbiome: Current Landscape and Future Opportunities. Int J Mol Sci, 24. Prajapati, S, et al. (2025). Microbiome and Postbiotics in Skin Health. Biomedicines, 13. Harris-Tryon, T, et al. (2022). Microbiota and Maintenance of Skin Barrier Function. Science, 376, 940–945. Scharschmidt, T, et al. (2025). Skin Microbiome and Dermatologic Disorders. J Clin Invest, 135.

View All

Other Pages (66)

  • Careers | Sequential

    Job Listings Job Type Select Job Type Workspace Select Workspace Search Jobs Number of jobs found: 3 Laboratory Technician Cambridge, UK View Job Marketing Associate Cambridge, UK View Job Sales Associate (NYC Based) New York, NY, USA View Job

  • Intimate Care Testing | Sequential

    Evaluate intimate care products and treatments and their effect on the vulvovaginal environment, with human and microbiome biomarkers. Clinical Testing for Intimate Care Formulations Generate robust human evidence for intimate care products and therapeutic formulations. From efficacy to mechanisms of action, Sequential helps you understand how your formulation affects intimate health in real people. Design your study Compare methods Cleansers Gels Lubricants Wipes Menstrual Barrier Cream Moisturising Cream Validate Your Intimate Care Formulations From Everyday Intimate Care to Targeted Treatments Sequential provides cutting-edge testing designed to work with all types of intimate product lines and formulations. We take into account your product's desired outcome to ensure that all critical questions about efficacy and impact are measured using clinical data. Design your study What can we help you prove Build Evidence Around The Questions That Matter Clinical Efficacy Demonstrate measurable product performance. Novel Claims Generate evidence to support differentiated claims. Mechanism of Action Understand how and why your formulation works. Product Differentiation Compare formulations, ingredients or concentrations. What can we measure Go Beyond Traditional Clinical Endpoints Build a deeper picture of intimate health by combining molecular, microbial and clinical data. Explore biological response, microbial ecology and mechanisms that traditional endpoints alone may not reveal. Human Biomarkers Measure molecular responses and investigate biological pathways relevant to intimate health and your formulation. Find out more Read More Study design Built Around Your Research Question From exploratory microbiome and biomarker studies to efficacy-focused clinical research, we tailor study design, recruitment, sampling and analysis to your intimate care formulation, population and objectives. Design Recruit Collect Analyse Interpret Why Leading Brands Choose Sequential 50,000+ Sample Database 4,000+ Ingredients Database 10,000+ Participant Database Case Study Clinically shown to maintain vaginal pH and protective Lactobacillus Species-level testing in 30 participants found no overgrowth of potentially harmful bacteria. Request the case study What do I do next? Planning an Intimate Care Study? Tell us about your product and what you're looking to prove. We'll help you identify the right study design and measurements. Design Your Study Dive Deeper Into Intimate Care Check out our collection of scientific papers, peer-reviewed research, and in-depth clinical articles. Vaginal Multiomics: Understanding the System, Not the Signal Oct 1 2 min read Beyond pH Feb 10 2 min read Female reproductive tract - Gut axis: everything is connected Oct 2, 2025 3 min read 1 2 3 4 5

  • Advanced Testing for Personal Care & Therapeutics | Sequential

    Specialist CRO trusted by 100+ brands to unlock the science behind personal care and therapeutics, with biomarker evidence for skin, scalp, oral and more. The Future of Next Generation Ingredients & Validation Expect sharp, insightful sessions focused on real innovation and go-to-market cases. Sign up to our event today. Dermocosmetics Pharma Therapeutics CRO Partnerships Ingredient Manufacturers Your End-to-End Clinical Research Partner Human clinical testing, biomarker discovery, and next-generation formulations powered by the world's most advanced multi-omics platform. 50,000+ 4,000+ 10,000+ 100+ Sample Database Ingredients Database Recruitment Database Industry Partners What We Offer From study design and participant recruitment to laboratory analysis and data interpretation, Sequential delivers an end-to-end, in-house solution for understanding how products interact in real use cases. Our clinically relevant insights translate complex microbial and molecular data into clear, actionable outcomes empowering companies to develop products that are credible, effective, and trusted by consumers. Start a study Supporting World-Class Clients & Partners Join Our Partners! What Our Clients Say “Sequential is one of the world’s most innovative Microbiome companies. The resolution at subspecies level, and to perform quantification of key vaginal microbes, in vivo , was exactly what we wanted at Curive Healthcare to know intricately how our product is working to improve women’s health.” - Matthew Line, Chief Marketing Officer at Curive Healthcare

View All
bottom of page